Search
forResearch 10 of 827
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- JAK 1-3 inhibitors and TYK-2 inhibitors in dermatology: Practical pearls for the primary care physician
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Association of JAK 1 and JAK 2 gene polymorphism with alopecia areata risk: a case–control genetic study
- The Effect of JAK Inhibitor on the Survival, Anagen Re-Entry, and Hair Follicle Immune Privilege Restoration in Human Dermal Papilla Cells
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Evaluation of the level of serum Interleukins (IL-2, IL-4, IL-15 andIL-17) and its relationship with disease severity in patients with alopecia areata
- Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →